http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2598385-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_085bf06143132bea5898c10dad5bd131 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5025 |
| filingDate | 2011-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89335d55a4376a265497414d6d750c9e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89886acb6db8225191c0d0dd1e76ce20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fa688e6bc16d3ecdec76a749d4c7204 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ec7e542d04fc5e904bf0ef13abfb1f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c1f71ce7a969a67d606a2177a7d5a50 |
| publicationDate | 2016-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2598385-C2 |
| titleOfInvention | 2-ARYLIMIDAZO[1,2-b]PYRIDAZINE,2-PHENYLIMIDAZO[1,2-a]PYRIDINE AND 2-PHENYLIMIDAZO[1,2-a]PYRAZINE DERIVATIVES |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to a compound of formula or a pharmaceutically acceptable salt thereof. Disclosed compounds have inhibitory activity on Hedgehog pathway activation and can be effective in treating pancreatic cancer or prostate cancer. In formula R 1 is a pyridyl, optionally substituted in position where substitution is possible with one or more R 8 ; R 2 is CN, C 1 -C 6 alkyl, C 3 -C- 8 cycloalkyl, phenyl, 5-6-member heteroaryl, where 1-2 members are heteroatoms selected from N and O, 4-5-member heterocyclyl, where 1 member is a heteroatom selected from a group consisting of N, where each alkyl, cycloalkyl, phenyl or heterocyclyl group is optionally substituted in position where substitution is possible with one or more R 10 ; R 3 is halogen, C 1 -C- 6 alkyl, C 1 -C 6 haloalkyl or C 3 -C 8 cycloalkyl; A is a bond,-N(R 7 )-, -N(R 7 )C(O)-, N(R 7 )C(O)N(R 7 )-, -C(O)O-, -S(O) 2 N(R 7 )- or-N(R 7 )S(O) 2 -; each R 5 is independently hydrogen, C 1 -C 6 alkyl; each Z is independently CR 6 ; each R 6 is independently hydrogen, halogen. Invention also relates to a pharmaceutical composition containing disclosed compound, a method of inhibiting Hedgehog signaling pathway and use of compounds. n EFFECT: technical result is obtaining novel compounds having inhibitory activity on Hedgehog pathway activation. n 19 cl, 3 dwg, 5 tbl, 706 ex |
| priorityDate | 2010-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1569.